Related Experiment Videos
Thymidine phosphorylase and breast carcinoma
Qifeng Yang1, Goro Yoshimura, Ichiro Mori
1Second Department of Pathology, Wakayama Medical College, Wakayama City, Japan. yang-qf@mall.wakayama-med.ac.jp
Anticancer Research
|August 15, 2002
Summary
Thymidine phosphorylase (TP) is an enzyme linked to breast cancer, but its role in tumor angiogenesis remains debated. Further standardization is needed for its use as a prognostic marker.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Thymidine phosphorylase (TP), also known as platelet-derived endothelial-cell growth factor (PD-ECGF), catalyzes thymidine dephosphorylation.
- TP exhibits angiogenic properties, though the mechanism is unclear.
- Elevated TP expression is observed in various solid tumors, including breast carcinoma.
Purpose of the Study:
- To investigate the role of TP as a biological marker in breast carcinoma.
- To clarify the conflicting results regarding TP's effect on tumor angiogenesis.
Main Methods:
- Review of existing clinical and experimental studies on TP expression and function in breast cancer.
- Analysis of data on TP's correlation with tumor angiogenesis and patient outcomes.
Main Results:
- Clinical studies on TP as a breast carcinoma marker have yielded conflicting results.
- Evidence suggests TP has minimal impact on invasive breast carcinoma angiogenesis.
- Emerging data indicate TP may be a marker for response to pyrimidine analogues.
Conclusions:
- Standardization of scoring techniques and cut-off levels is crucial for TP's clinical application in prognostic testing.
- Further research is needed to establish TP's definitive role in breast cancer prognosis and treatment stratification.